Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 25, Issue 29, Pages 4536-4541Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2007.11.5154
Keywords
-
Categories
Ask authors/readers for more resources
Purpose Bevacizumab (Bev) has clinical activity in advanced renal cell carcinoma (RCC), and, when combined with erlotinib (Erl), has shown encouraging objective response rate (ORR) and progression-free survival (PFS). We performed a phase II, randomized, double-blind, multicenter, placebo-controlled trial to assess whether Erl provides additional clinical benefit with regard to PFS and ORR when combined with Bev in first-line treatment of metastatic RCC. Patients and Methods One hundred four patients received intravenous Bev (10 mg/kg) every 2 weeks in combination with oral Erl (150 mg) or placebo daily. Patients were treated until progression or toxicity. Results A landmark analysis was performed 9 months after enrollment was completed (median follow-up, 9.8 months). Sixty-five patients had discontinued therapy; time to study discontinuation did not differ between the two treatment groups. The median PFS was 9.9 months (Bev + Erl [B + E]) versus 8.5 months (Bev; hazard ratio = 0.86; 95% Cl, 0.5 to 1.49; P = .58). ORR (complete plus partial) was 14% (B + E) versus 13% (Bev). One complete response occurred in the B + E group. Median survival was 20 months for B + E but not reached for Bev. The most common grade 3/4 adverse events (> 5% of patients) were hypertension, rash, proteinuria, diarrhea, and hemorrhage. One treatment-related death occurred on study (Gl perforation, B + E group). Conclusion The addition of Erl to Bev was well tolerated, but did not provide additional clinical benefit compared with Bev alone. Bev has encouraging clinical activity for previously untreated metastatic RCC patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available